Riik: Kanada
keel: inglise
Allikas: Health Canada
ALLOPURINOL
MARCAN PHARMACEUTICALS INC
M04AA01
ALLOPURINOL
200MG
TABLET
ALLOPURINOL 200MG
ORAL
30/100/500/1000
Prescription
ANTIGOUT AGENTS
Active ingredient group (AIG) number: 0103654002; AHFS:
APPROVED
2012-11-22
_ _ _MAR-Allopurinol PM_ _ _ _ _ _Page 1 of 26_ _ _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR MAR-ALLOPURINOL Allopurinol Tablets Tablets, 100, 200 and 300 mg, oral USP Xanthine Oxidase Inhibitor Marcan Pharmaceuticals Inc. 2 Gurdwara Road, Suite #112 Ottawa, Ontario K2E 1A2 Submission Control Number: 265172 Date of Initial Authorization: NOV 22, 2012 Date of Revision: JUL 13, 2022 _ _ _MAR-Allopurinol PM_ _ _ _ _ _Page 2 of 26_ _ _ RECENT MAJOR LABEL CHANGES 3 Serious Warnings and Precautions Box 07/2022 4 Dosage and Administration, 4.2 Recommended Dose and Dosage Adjustment 07/2022 7 Warnings and Precautions 07/2022 7 Warnings and Precautions, 7.1.4 Geriatrics 07/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics ................................................................................................................... 4 1.2 Geriatrics .................................................................................................................... 4 2 CONTRAINDICATIONS .................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX .............................................................. 5 4 DOSAGE AND ADMINISTRATION .................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment .......................................................... 5 4.5 Missed Dose ................. Lugege kogu dokumenti